Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference

NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
June 11, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas Appoints Linda Bain to its Board of Directors

NEW HAVEN, Conn., June 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
June 05, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference

NEW HAVEN, Conn., June 05, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
May 29, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer

- Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response - - Data represent the first demonstration of PROTAC®-mediated degradation...
May 20, 2020 16:30 ET | Source: Arvinas Inc.

Arvinas to Hold Virtual 2020 Annual Meeting of Stockholders

NEW HAVEN, Conn., May 20, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
May 13, 2020 17:49 ET | Source: Arvinas Inc.

Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer

- Describes the first evidence of clinical benefit for PROTAC® protein degraders, a novel therapeutic modality - - Data to be presented during the 2020 American Society of Clinical Oncology (ASCO)...
April 28, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update

NEW HAVEN, Conn., April 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
April 13, 2020 16:54 ET | Source: Arvinas Inc.

Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic

NEW HAVEN, Conn., April 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
March 31, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas to Present at the American Society of Clinical Oncology Annual Meeting

NEW HAVEN, Conn., March 31, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
March 16, 2020 07:00 ET | Source: Arvinas Inc.

Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., March 16, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...